CLOVES Syndrome Pediatric Research and Clinical Trials

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Contact the Vascular Anomalies Center

Research & Innovation

  • Matthew Warman, MD, director of Boston Children’s Orthopedic Research Laboratories, and Kyle Kurek, MD, staff pathologist, are leading an initiative that has already revealed the genetic basis for CLOVES: a mutation in a gene known as PIK3CA.

    Next, the team hopes to develop models to understand how mutations in PIK3CA cause malformation and overgrowth, and to determine which drugs and other therapies can be used safely and successfully to improve the lives of individuals with CLOVES and other conditions with similar clinical characteristics. Learn more.
  • Boston Children’s has been identified as the second national site for a clinical trial of a drug called sirolimus—which has proven effective in slowing the growth of certain tumors—in children with complex vascular anomalies, such as those found in CLOVES syndrome.

    The Boston Children’s trial will be led by Cameron C. Trenor III, MD, co-director of the hospital’s Cerebrovascular Disorders and Stroke Program. Learn more.
  • Ahmad Alomari, MD, MSc, FSIR, co-director of Boston Children’s Vascular Anomalies Center, and his colleagues have collected data characterizing many clinical findings related to CLOVES syndrome. They are now beginning the data analysis phase. 
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944